Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) fell 295.93% to $7.87 in Q4 2025 from the same period last year, while for Dec 2025 it was $41.57, marking a year-over-year increase of 845.29%. This contributed to the annual value of $41.48 for FY2025, which is 818.99% up from last year.
Latest data reveals that Regeneron Pharmaceuticals reported EPS (Weighted Average and Diluted) of $7.87 as of Q4 2025, which was down 295.93% from $13.62 recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of $27.97 during Q2 2021, and its lowest value of $6.27 during Q1 2024.
Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was $10.15 (2021), whereas its average is $11.25.
In the last 5 years, Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) skyrocketed by 26754.27% in 2021 and then crashed by 7329.28% in 2022.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $19.68 in 2021, then crashed by 46.7% to $10.49 in 2022, then decreased by 2.76% to $10.2 in 2023, then dropped by 20.49% to $8.11 in 2024, then fell by 2.96% to $7.87 in 2025.
Its EPS (Weighted Average and Diluted) was $7.87 in Q4 2025, compared to $13.62 in Q3 2025 and $12.81 in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value